跳到正文
原文
Endpoints News 生物医药· Elizabeth Cairns·· 2026-10-15AI 评分45

Osivax 流感疫苗 IIb 期试验失利后转向联合策略

Osivax pivots to combo approach after flu jab fails in Phase 2b

AI 导读

法国生物技术公司 Osivax 的主要流感疫苗在 IIb 期中期试验中表现失败。尽管该项目受挫,Osivax 仍对该管线抱有希望,并计划调整策略,将其与其他药物进行联合开发。

正文

Os­i­vax’s lead flu vac­cine has flopped in a mid-stage tri­al. But the French biotech still holds out hope for the pro­gram, and plans to com­bine …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news